CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Baird Downgrades Karyopharm Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $15

Negative
AI Analysis

Summary

Baird downgraded Karyopharm Therapeutics from Outperform to Neutral and reduced its price target from $15 to $3, reflecting a significant reassessment of the company's outlook.

Importance:5/10
Sentiment:
-0.80
analyst_downgradeprice_target_reductionrating_change
Related Companies

Read the original article

Published by yahoo_finance on July 31, 2026 11:26 AM

Read Original